Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Buy
54
CRLBF Quote, Financials, Valuation and Earnings
Last price:
$1.2700
Seasonality move
:
402.59%
Day range:
$1.2200 - $1.3400
52-week range:
$0.4256 - $2.3000
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
0.67x
P/B ratio:
1.07x
Volume:
580.9K
Avg. volume:
2M
1-year change:
50.59%
Market cap:
$457.5M
Revenue:
$724.3M
EPS (TTM):
-$0.15
Analysts' Opinion
-
Consensus RatingCresco Labs, Inc. has received a consensus rating of Buy. The company's average rating is a Buy based on 7 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $2.0000, Cresco Labs, Inc. has an estimated upside of 56.25% from its current price of $1.2800.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $2.0000 representing 100% downside risk from its current price of $1.2800.
Fair Value
-
According to the consensus of 7 analysts, Cresco Labs, Inc. has 56.25% upside to fair value with a price target of $2.0000 per share.
CRLBF vs. S&P 500
-
Over the past 5 trading days, Cresco Labs, Inc. has underperformed the S&P 500 by -34.13% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Cresco Labs, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Cresco Labs, Inc. revenues have been falling on a year-over-year basis for 13 quarters in a row. In the most recent quarter Cresco Labs, Inc. reported revenues of $164.9M.
Earnings Growth
-
Cresco Labs, Inc. earnings have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Cresco Labs, Inc. reported earnings per share of -$0.05.
Enterprise value:
871.4M
EV / Invested capital:
0.95x
Price / LTM sales:
0.67x
EV / EBIT:
10.38x
EV / Revenue:
1.30x
PEG ratio (5yr expected):
--
EV / Free cash flow:
20.78x
Price / Operating cash flow:
10.75x
Enterprise value / EBITDA:
6.09x
Gross Profit (TTM):
$306.4M
Return On Assets:
-3.76%
Net Income Margin (TTM):
-7.56%
Return On Equity:
-13.84%
Return On Invested Capital:
-5.05%
Operating Margin:
14.94%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | $782.2M | $736.7M | $670.2M | $179.8M | $164.9M | |
| Gross Profit | $333.3M | $350.3M | $306.4M | $87.7M | $74.3M | |
| Operating Income | $34.3M | $117.9M | $84M | $29.3M | $24.6M | |
| EBITDA | $97.7M | $190.2M | $143.1M | $45.9M | $39.3M | |
| Diluted EPS | -$1.08 | -$0.20 | -$0.15 | -$0.03 | -$0.05 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $449M | $355.2M | $303.2M | $311.9M | $242.6M | |
| Total Assets | $1.6B | $1.8B | $1.4B | $1.4B | $1.3B | |
| Current Liabilities | $209.2M | $270.6M | $260.9M | $158.6M | $97.4M | |
| Total Liabilities | $857.7M | $984.8M | $973.3M | $1B | $940.2M | |
| Total Equity | $712.3M | $771.4M | $425.9M | $365.4M | $340.2M | |
| Total Debt | $584.7M | $655.1M | $667.5M | $679.3M | $571.8M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $67.6M | $99.8M | $73.3M | $49.2M | $6.3M | |
| Cash From Investing | -$61.3M | -$19.7M | -$30.5M | -$6.2M | -$6.2M | |
| Cash From Financing | -$26.2M | -$33.2M | -$122.2M | -$2.5M | -$72.3M | |
| Free Cash Flow | $1.1M | $74.6M | $41.9M | $42.9M | -$1.3M | |
CRLBF
Sector
Market Cap
$457.5M
$27.8M
Price % of 52-Week High
55.65%
51.03%
Dividend Yield
0%
0%
Shareholder Yield
4.29%
-1.55%
1-Year Price Total Return
50.59%
-17.47%
Beta (5-Year)
1.118
0.518
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$1.4191
200-day SMA
Buy
Level
$0.8816
Bollinger Bands (100)
Buy
Level
0.8685 - 1.3685
Chaikin Money Flow
Sell
Level
-73.6M
20-day SMA
Buy
Level
$1.0462
Relative Strength Index (RSI14)
Buy
Level
54.0985
ADX Line
Buy
Level
29.3314
Williams %R
Neutral
Level
-64.561
50-day SMA
Buy
Level
$1.0779
MACD (12, 26)
Buy
Level
0.1053
25-day Aroon Oscillator
Buy
Level
80
On Balance Volume
Neutral
Level
5.9M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-0.2192)
Sell
CA Score
(Annual)
Level (-0.5258)
Buy
Beneish M-Score
(Annual)
Level (-3.2499)
Buy
Momentum Score
Level (3)
Sell
Ohlson Score
Level (2.6692)
Buy
Piotroski F Score
(Annual)
Level (7)
Buy
Quality Ratio Score
Level (7)
Buy
Fundamental Score
Level (3)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Cresco Labs Inc. engages in cultivating medical grade cannabis, manufacturing medical products derived from cannabis cultivation, and distributing such products to medical or adult use consumers. It focuses on regulatory compliance while working to develop condition-specific strains of cannabis and non-invasive delivery methods. The company was founded by Charles Bachtel, Joseph Caltabiano, Dominic Sergi, Rob Sampson, and Brian McCormack on July 6, 1990 and is headquartered in Chicago, IL.
Stock Forecast FAQ
In the current month, CRLBF has received 7 Buy ratings 0 Hold ratings, and 0 Sell ratings. The CRLBF average analyst price target in the past 3 months is $2.0000.
-
Where Will Cresco Labs, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Cresco Labs, Inc. share price will rise to $2.0000 per share over the next 12 months.
-
What Do Analysts Say About Cresco Labs, Inc.?
Analysts are divided on their view about Cresco Labs, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Cresco Labs, Inc. is a Sell and believe this share price will drop from its current level to $2.0000.
-
What Is Cresco Labs, Inc.'s Price Target?
The price target for Cresco Labs, Inc. over the next 1-year time period is forecast to be $2.0000 according to 7 Wall Street analysts, 7 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is CRLBF A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Cresco Labs, Inc. is a Buy. 7 of 7 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of CRLBF?
You can purchase shares of Cresco Labs, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Cresco Labs, Inc. shares.
-
What Is The Cresco Labs, Inc. Share Price Today?
Cresco Labs, Inc. was last trading at $1.2700 per share. This represents the most recent stock quote for Cresco Labs, Inc.. Yesterday, Cresco Labs, Inc. closed at $1.2800 per share.
-
How To Buy Cresco Labs, Inc. Stock Online?
In order to purchase Cresco Labs, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Related Companies
Get CRLBF Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
CRLBF
Sector
P/E ratio
--
23.89x
PEG ratio
--
-0.01x
P/B ratio
1.07x
1.82x
Price / LTM sales
0.67x
1.60x
Growth Metrics
CRLBF
Sector
Revenue growth
-8.27%
4.62%
Earnings growth
-58.42%
10.88%
Revenue (5-year growth)
41.31%
6.5%
Earnings forecast
-$0.04
-$0.21
Profitability
CRLBF
Sector
Profitability FY 2024
$342.7M
$3.5M
Return on invested capital
-5.05%
-31.77%
Return on assets
-3.76%
-27.96%
Return on equity
-13.84%
-37.63%
Earnings Date
Last Earnings Date
Nov
5
Next Earnings Date
Mar
11
Estimated Next Earnings Date
Feb
4
Balance Sheet
CRLBF
Sector
Total cash
$78.7M
$26.3M
Short term investments
--
$25.7M
Total assets
$1.4B
$78M
Long term debt
$571.8M
$3.3M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is SentinelOne Stock Undervalued?
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Is Broadcom Stock on Sale?
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Stock Ideas
Buy
57
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
80
TVTX alert for Dec 26
Travere Therapeutics, Inc. [TVTX] is down 1.29% over the past day.
Buy
68
KOD alert for Dec 26
Kodiak Sciences, Inc. [KOD] is down 5.28% over the past day.
Buy
64
ZCSH alert for Dec 23
Grayscale Zcash Trust (ZEC) [ZCSH] is down 0% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
